CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Truist raised the firm’s price target on Eli Lilly (LLY) to $1,038 from $1,029 and keeps a Buy rating on the shares. The firm is updating its ...

Evaluate the expected performance of Lilly (LLY) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart ...

Eli Lilly & Co. faced a skeptical Seventh Circuit Tuesday in arguing a lower court used a misplaced two-step process when it ...

Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 36.07% higher than today’s price of $756.99.

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes chronic abdominal pain.

Eli Lilly pre-announced a sizable Q4 2024 revenue miss headed into the big J.P. Morgan healthcare investor conference, but the biopharma reported massive growth. A lot of the quarterly ...